BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$3.89 -0.05 (-1.27%)
At close: Oct 2, 2026 · 4:00 PM EDT

BridgeBio Oncology Therapeutics (BBOT) Other Accumulated Expenses (2024 - 2026)

Updated

BridgeBio Oncology Therapeutics (BBOT) reported Other Accumulated Expenses of $195,000 for Q2 2026, down 64.2% from the prior quarter.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Other Accumulated Expenses (2024 - 2026) Analysis & Trends

At the end of FY2025, BridgeBio Oncology Therapeutics posted Other Accumulated Expenses of $240,000, up 44.6% from FY2024.

  • By year, Other Accumulated Expenses came in at $166,000 in FY2024.
  • Five-year quarterly Other Accumulated Expenses spans a low of $166,000 in Q4 2024 and a high of $545,000 in Q1 2026.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $545,000 (Q1 2026), $240,000 (Q4 2025) and $178,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 BridgeBio Oncology Therapeutics 311.65 Mn -1.06 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 195,000.00
Mar 31, 2026 545,000.00
Dec 31, 2025 240,000.00
Sep 30, 2025 178,000.00
Dec 31, 2024 166,000.00
API Access

BridgeBio Oncology Therapeutics Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=BBOT&period=max&api_key=YOUR_API_KEY